SLCO1B1 and myopathy: Probably the best example of GWAS applied to drug outcomes in conditions other than diabetes was the finding that variants in SLCO1B1 (encoding the statin transporter OATP1B1) increase the risk of statin‐associated myopathy, with 2% of the population who carried two c‐alleles at rs4140956 being 16 times more likely to develop severe myopathy with simvastatin.